tiprankstipranks
China Touyun Tech Group Ltd (HK:1332)
:1332
Hong Kong Market

China Touyun Tech Group (1332) AI Stock Analysis

1 Followers

Top Page

HK:1332

China Touyun Tech Group

(1332)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 5.2)
Rating:41Neutral
Price Target:
HK$0.09
▼(-58.10% Downside)
Action:UpgradedDate:01/28/26
The score is driven primarily by very weak financial performance—ongoing losses, negative equity, and poor cash flow—indicating elevated balance-sheet and funding risk. Technicals also remain strongly bearish with the price far below key moving averages and negative MACD, while valuation provides limited support given the negative P/E and lack of dividend data.
Positive Factors
Gross profitability
The company still reports a positive gross profit margin, indicating product-level pricing covers variable costs. That persistent gross margin provides a structural buffer for returning to operating profitability if fixed costs and SG&A are reduced or volumes recover, supporting medium-term recovery.
Negative Factors
Negative equity / insolvency risk
Negative shareholders' equity is a structural red flag that constrains financing options and increases creditor bargaining power. Over months this condition limits access to new capital, raises likelihood of restructuring or asset sales, and undermines the firm's ability to execute medium-term strategic plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross profitability
The company still reports a positive gross profit margin, indicating product-level pricing covers variable costs. That persistent gross margin provides a structural buffer for returning to operating profitability if fixed costs and SG&A are reduced or volumes recover, supporting medium-term recovery.
Read all positive factors

China Touyun Tech Group (1332) vs. iShares MSCI Hong Kong ETF (EWH)

China Touyun Tech Group Business Overview & Revenue Model

Company Description
Touyun Biotech Group Limited, an investment holding company, designs, develops, manufactures, and sells packaging products in Hong Kong, the People's Republic of China, Europe, North and South America, and internationally. It operates through four...
How the Company Makes Money
China Touyun Tech Group generates revenue through multiple streams, including subscription fees for its cloud services, licensing fees for its software products, and consulting services related to big data and AI implementation. Additionally, the ...

China Touyun Tech Group Financial Statement Overview

Summary
Financial statements indicate severe weakness: declining revenues, negative EBIT/EBITDA and net income, negative stockholders’ equity (insolvency risk), substantial liabilities relative to assets, and weak cash generation with zero latest operating cash flow and negative free cash flow.
Income Statement
25
Negative
Balance Sheet
15
Very Negative
Cash Flow
20
Very Negative
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue117.22M159.97M198.64M315.82M283.50M206.79M
Gross Profit49.21M72.07M56.60M120.12M107.05M84.61M
EBITDA-34.16M-27.92M-228.57M-144.39M-83.13M-87.22M
Net Income-28.89M-88.11M-268.94M-198.06M-72.95M-168.78M
Balance Sheet
Total Assets613.22M550.32M607.34M887.70M1.02B971.94M
Cash, Cash Equivalents and Short-Term Investments11.53M69.64M36.04M144.25M93.95M254.40M
Total Debt400.72M384.59M384.91M395.01M317.37M222.62M
Total Liabilities619.38M590.96M586.27M604.19M537.68M415.57M
Stockholders Equity-63.84M-83.20M-848.00K263.96M469.92M488.04M
Cash Flow
Free Cash Flow-1.94M-53.54M-13.49M-39.30M-304.60M-140.86M
Operating Cash Flow431.00K-49.87M3.65M-26.37M-53.81M-15.35M
Investing Cash Flow23.99M-4.66M-70.95M-17.25M-147.74M-47.87M
Financing Cash Flow23.37M35.74M-27.68M102.63M123.17M160.47M

China Touyun Tech Group Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.21
Price Trends
50DMA
0.14
Positive
100DMA
0.21
Negative
200DMA
0.16
Positive
Market Momentum
MACD
<0.01
Positive
RSI
50.77
Neutral
STOCH
25.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1332, the sentiment is Negative. The current price of 0.21 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.14, and above the 200-day MA of 0.16, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.77 is Neutral, neither overbought nor oversold. The STOCH value of 25.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1332.

China Touyun Tech Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
HK$1.52B12.115.45%11.43%35.10%12.47%
61
Neutral
$18.38B12.79-2.54%3.03%1.52%-15.83%
50
Neutral
HK$679.71M36.559.89%0.59%-2.08%-23.18%
46
Neutral
HK$757.59M-15.70-5.51%3.20%3.51%-950.83%
46
Neutral
HK$16.27M3.59-4.29%-44.08%
41
Neutral
HK$462.98M26.70-46.63%-30.86%87.59%
* Consumer Cyclical Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1332
China Touyun Tech Group
0.17
>-0.01
-5.17%
HK:0468
Greatview Aseptic Packaging Company
2.50
0.00
0.00%
HK:0716
Singamas Container Holdings
0.64
0.11
21.67%
HK:1820
Pacific Millennium Packaging Group Corp.
2.52
-2.38
-48.57%
HK:6898
China Aluminum Cans Holdings Ltd.
0.72
0.28
63.64%
HK:8291
Wan Cheng Metal Packaging Company Limited
0.31
-0.09
-21.79%

China Touyun Tech Group Corporate Events

Touyun Biotech Details Financing and Asset Moves to Address Audit Qualification and Support Growth
Dec 31, 2025
Touyun Biotech Group Limited has outlined a series of measures to address an audit disclaimer of opinion and alleviate going-concern uncertainties, centering on expanding its health products portfolio, strengthening distribution channels, and shor...
Touyun Biotech Faces Loan Repayment Challenges
Dec 11, 2025
Touyun Biotech Group Limited has announced that its subsidiary, Shanxi Touyun Biotechnology Co., Ltd., has failed to repay a loan of RMB90 million by its maturity date, resulting in an aggregated overdue loan amount of RMB150 million. The company ...
Touyun Biotech Announces CEO Remuneration Changes
Nov 6, 2025
Touyun Biotech Group Limited has released supplemental information related to the remuneration of its CEO, Ms. Amy Ha, for the years 2022 and 2023. The announcement highlights a significant decrease in her remuneration from HK$3,102,000 in 2022 to...
Touyun Biotech Announces Strategic Cooperation Amid Unusual Market Activity
Nov 3, 2025
Touyun Biotech Group Limited announced an unusual increase in its share price and trading volume, with no known reasons for these movements. The company confirmed that its operations remain normal and disclosed a strategic cooperation agreement wi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 28, 2026